United States Patent 8,900,554: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
The United States Patent 8,900,554, titled "Foamable composition and uses thereof," was granted to Foamix Pharmaceuticals Ltd. on December 2, 2014. This patent is significant in the field of pharmaceutical and cosmetic formulations, particularly for treating parasitic infestations and skin conditions. Here, we delve into the scope, claims, and the broader patent landscape surrounding this invention.
Inventors and Assignee
The patent was invented by Dov Tamarkin, Doron Friedman, and Meir Eini, and it is assigned to Foamix Pharmaceuticals Ltd., a company based in Rehovot, Israel[4].
Background of the Invention
The invention addresses the need for a safe and effective foamable composition that can be used to treat subjects infested with parasitic arthropodes, such as lice and mites, and to alleviate skin and eye irritation associated with existing treatments. Traditional pediculocide shampoos and cream rinses often cause irritation, making the development of a gentler yet effective alternative crucial[4].
Scope of the Invention
The patent covers a foamable composition that includes a combination of ingredients such as:
- An active ingredient, which can be an insecticide or a therapeutic agent.
- A solvent system.
- A surface-active agent.
- A foam adjuvant.
- Optional ingredients like vitamins, acids, and other additives[4].
This composition is designed to be easy to apply, non-irritating, and effective in treating various skin conditions and parasitic infestations.
Claims of the Patent
The patent includes multiple claims that define the scope of the invention. Here are some key claims:
Independent Claims
- Claim 1: A foamable composition comprising an active ingredient, a solvent system, a surface-active agent, and a foam adjuvant.
- Claim 10: A method of treating a subject infested with a parasitic arthropode using the foamable composition[4].
Dependent Claims
- Claims 2-9: Various modifications and specific embodiments of the foamable composition, including different types of solvents, surface-active agents, and foam adjuvants.
- Claims 11-15: Methods of treating specific conditions such as pediculosis, scabies, and acne using the foamable composition[4].
Prior Art and References
The patent cites numerous prior art references, including earlier patents related to foamable compositions, insecticides, and therapeutic agents. These references highlight the evolution of similar technologies and the innovations introduced by the current patent[1][4].
Patent Landscape
Related Patents
The patent landscape in this area is rich with similar inventions aimed at improving pharmaceutical and cosmetic formulations. For example:
- U.S. Patent 7,820,145 B2, also by Tamarkin et al., covers foamable compositions for treating skin conditions.
- U.S. Patent 8,114,385 B2, another patent by Tamarkin et al., deals with foamable compositions for topical administration[1].
Litigation and Enforcement
The '554 patent has been involved in legal proceedings, such as the case between Bayer Healthcare Pharmaceuticals and Perrigo UK Finco, where claims of the '554 patent were part of the dispute[2].
Economic and Research Implications
The Patent Claims Research Dataset by the USPTO provides insights into the scope and trends of patent claims, including those related to pharmaceutical and cosmetic compositions. This dataset can help in understanding the broader patent landscape and the economic impact of such inventions[3].
Industry Impact
The foamable composition patented in US 8,900,554 has significant implications for the pharmaceutical and cosmetic industries. It offers a safer and more effective alternative for treating parasitic infestations and skin conditions, which can improve patient compliance and outcomes.
Market Potential
The market for topical treatments is substantial, and innovations like the foamable composition can capture a significant share. The ease of use and reduced irritation make it an attractive option for both consumers and healthcare providers.
Competitive Advantage
Foamix Pharmaceuticals Ltd. gains a competitive advantage with this patent, as it protects their unique formulation and method of treatment. This can help the company to differentiate its products in a crowded market.
Conclusion
The United States Patent 8,900,554 is a critical invention in the field of pharmaceutical and cosmetic formulations. It addresses significant issues related to skin and eye irritation and provides a safe and effective treatment option. Understanding the scope, claims, and the broader patent landscape is essential for both industry professionals and researchers.
Key Takeaways
- Innovation in Formulation: The patent introduces a novel foamable composition that is non-irritating and effective.
- Broad Applications: The composition can be used to treat various parasitic infestations and skin conditions.
- Legal and Economic Implications: The patent has been involved in legal disputes and contributes to the economic landscape of pharmaceutical and cosmetic innovations.
- Industry Impact: The invention offers a competitive advantage and significant market potential.
FAQs
Q: What is the primary use of the foamable composition described in US 8,900,554?
A: The primary use is to treat subjects infested with parasitic arthropodes and to alleviate skin and eye irritation associated with existing treatments.
Q: Who are the inventors of the patent?
A: The inventors are Dov Tamarkin, Doron Friedman, and Meir Eini.
Q: What company is assigned the patent?
A: The patent is assigned to Foamix Pharmaceuticals Ltd.
Q: What are some of the key ingredients in the foamable composition?
A: The composition includes an active ingredient, a solvent system, a surface-active agent, and a foam adjuvant.
Q: Has the patent been involved in any legal proceedings?
A: Yes, the patent has been part of legal disputes, such as the case between Bayer Healthcare Pharmaceuticals and Perrigo UK Finco.
Sources
- United States Patent and Trademark Office. US 8,900,554 B2: Foamable composition and uses thereof. December 2, 2014.
- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT. Finacea (azelaic acid) - Bayer Healthcare Pharmaceuticals v. Perrigo UK Finco.
- United States Patent and Trademark Office. Patent Claims Research Dataset.
- Google Patents. US8900554B2 - Foamable composition and uses thereof. December 2, 2014.
